The introduction of the small molecule drug ibrutinib has transformed the treatment landscape of chronic lymphocytic leukaemia (CLL) over the past decade, offering better outcomes and patient experiences. Professor Patrick Thornton has played a key role in identifying the subset of patients who benefit most from the drug. The use of ibrutinib has evolved to include earlier treatment in the disease course, as well as combinations with other active oral agents like venetoclax. The future goal is to individualize treatment for each CLL patient using precision medicine with targeted agents, rather than chemotherapy, leading to significantly improved survival rates.
Source link
How the evolving landscape of chronic lymphocytic leukaemia (CLL) treatment is transforming outcomes
